Viral Vector and Plasmid DNA Manufacturing Market Demand to Peak in 2028 with Projected Industry Growth
The increasing incidence of HIV is expected to provide profitable growth opportunities for industry players engaged in the global market.
SEATTLE, WASHINGTON, USA, Jan 7, 2022 /EINPresswire.com/ – The viral vector and plasmid DNA manufacturing market is expected to be valued at US $ 427.2 million in 2019 and is expected to post a CAGR of 22.8% over the forecast period (2019-2027), as highlighted in a new report released by Coherent Market Insights.
The increasing incidence of HIV is expected to provide profitable growth opportunities for industry players engaged in the global market. For example, according to the Joint United Nations Program on HIV / AIDS in 2018, more than 37.9 million people were diagnosed with HIV, while 24.5 million people worldwide were receiving antiretroviral therapy until in June 2019.
𝐇𝐞𝐫𝐞 𝐓𝐨 𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 @ https://www.coherentmarketinsights.com/insight/request-sample/962
Various research institutes are focusing on the production of viral vectors and plasmid DNA, which is expected to further the growth of the market. For example, in October 2019, researchers at the National Institutes of Health developed a new viral vector, which is a vehicle for delivering gene therapy to patients with sickle cell anemia.
Browse 34 market data tables and 33 figures spread over 201 pages and an in-depth table of contents on “Viral Vector and Plasmid DNA Manufacturing Market” – Global Forecast to 2027, by Product Type (Vector viral (retroviral vectors, adenoviral vectors, lentiviral vectors, adeno) – associated viral vectors and others), plasmid DNA and non-viral DNA vectors), by therapeutic application (cancer, hereditary disorders, infectious diseases and others), by product final (DNA vaccines, gene therapy, immunotherapy and others), and by region (North America, Latin America, Europe, Asia-Pacific, Middle East and Africa)
𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 𝐎𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 @ https://www.coherentmarketinsights.com/insight/request-pdf/962
The major market players are focused on adopting business strategies such as mergers and acquisitions, collaborations, licensing agreements and partnerships, in order to expand their product portfolio and presence in the global market. For example, in April 2018, Vigene Biosciences Inc. (Vigene), a leading biotechnology company for the production and development of viral vectors, entered into a partnership with Virovek to use proprietary adeno-associated virus production technology. (AAV) from Vigene, where the baculovirus (BAC) expression system is used for the production of adeno-associated viruses (AAV). Vectors produced from BAC-to-AAV technology can infect and transduce large numbers of mammalian cells in vivo and in vitro.
Additionally, in December 2017, Lonza, Massachusetts Eye and Ear (MEE) and Akouos, a biotechnology company, entered into strategic licensing agreements to obtain the exclusive rights to design adeno-associated viral vector gene therapy (Anc- AAV) for hearing and balance. disorder.
Key Points of the Global Viral Vector and Plasmid DNA Manufacturing Market:
The global viral vector and plasmid DNA manufacturing market is expected to exhibit a CAGR of 22.8% during the forecast period, owing to the increasing incidence of cancer and infectious diseases. For example, according to the National Cancer Institute (NCI) estimate, in 2018, approximately 1,735,350 new cases of cancer were diagnosed in the United States. Additionally, in November 2019, Public Health England estimated that around 103,800 people were living with HIV in the UK in 2018.
Among product types, the viral vectors segment accounted for a significant market share in 2018, owing to the increasing funding for research and development of effective products to meet the growing demand for viral vectors. For example, in February 2018, Cobra Biologics and Symbiosis Pharmaceutical Services received 16-month collaborative funding of US $ 2.5 million from Innovate UK. Fund to help Cobra Biologics and Symbiosis Pharmaceutical Services increase commercial viral vector manufacturing capacities in the UK
Among therapeutic applications, the cancer segment accounted for a significant market share in 2018. An increasing prevalence of cancer is expected to drive the demand for gene therapies and provide favorable opportunities for clinical stage biopharmaceutical companies to develop and manufacture new gene therapies. For example, according to Cancer Research UK’s estimate, around 363,484 new cancer cases were diagnosed between 2014 and 2016 in the UK.
Companies operating in the global viral vector and plasmid DNA manufacturing market include Lonza Group AG, FinVector Vision Therapies, Cobra Biologics and Pharmaceutical Services, Sigma-Aldrich Co. LLC, VGXI, Inc., VIROVEK, SIRION Biotech GmbH , FUJIFILM Diosynth Biotechnologies USA, Inc., Sanofi, Cell and Gene Therapy Catapult, Brammer Bio, and MassBiologics.
𝗡𝗼𝘄 𝗔𝗻𝗱 𝗚𝗲𝘁 𝗙𝗹𝗮𝘁 𝟯𝟬% 𝗢𝗳𝗳
𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐓𝐡𝐢𝐬 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 @ https://www.coherentmarketinsights.com/insight/buy-now/962
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, custom research reports, and advisory services. We are known for our actionable insights and authentic reports in a variety of fields including aerospace and defense, agriculture, food and beverage, automotive, chemicals and materials, and virtually every field. and a comprehensive list of subdomains under the sun. We create value for our clients through our highly reliable and accurate reporting. We are also committed to playing a leading role in providing insight in various post-COVID-19 sectors and continuing to deliver measurable and sustainable results for our clients.
Coherent Market Insights Pvt. Ltd.
write us here
Visit us on social networks: